Cara Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Tvardi Therapeutics reported a reduced net loss in 2025 but faces substantial doubt about its ability to continue as a going concern, following a failed IPF trial and delays in its key HCC program.
Cara Therapeutics is exploring strategic alternatives, including a proposed merger with Tvardi Therapeutics, after discontinuing its clinical program in notalgia paresthetica.
Cara Therapeutics is focusing its resources on developing oral difelikefalin for neuropathic pruritus associated with notalgia paresthetica (NP) after discontinuing other programs.